Inspirex™ Liver
Bioengineered human liver graft for life-saving transplantation
PRESSING NEED
More liver grafts for transplant
The wait for a liver transplant is a race against time. Many patients remain on the transplant waiting list while facing complications, organ failure, or limited donor availability.
Inspirex™ Liver advances a potential liver transplant alternative for patients with limited treatment options and ongoing organ shortages.
MEDICAL BREAKTHROUGH
Inspirex™ Liver
Inspirex™ Liver is an investigational human whole-liver graft designed to increase the number of livers available for transplantation.
Produced using Xylyx Bio’s proprietary XC™ Platform, Inspirex Liver™ is created by providing systemic physiologic support via xenogeneic cross-circulation to repair injured donor livers that would otherwise go unused, with the goal of restoring them to meet standard transplant criteria.
IMPACT
Transforming the future of liver transplantation
Liver transplants have increased only incrementally over the past two decades despite rising clinical demand. The availability of Inspirex™ Liver may help expand access to transplantation, increase the number of viable donor organs, and reduce liver transplant waitlist mortality in the U.S.
Research surrounding the development of a functional human liver graft continues to advance new possibilities in transplant medicine and organ recovery.
- Organ Procurement & Transplant Network/Scientific Registry of Transplant Recipients. Annual Data Report, 2024.
REFERENCES
- Wu WK, Tumen A, Stokes JW, Ukita R, Hozain A, Pinezich M, O’Neill JD, et al. Cross-circulation for extracorporeal liver support in a swine model. ASAIO. 2022; 68(4): 561-570.
- Wu WK, Ukita R, Patel YJ, Cortelli M, Trinh VQ, Ziogas IA, et al. Xenogeneic cross-circulation for physiological support and recovery of ex vivo human livers. Hepatology. 2023; 78(3): 820-834.
- Shishido Y, Tracy KM, Wu WK, Cortelli M, Petrovic M, Harris TR, et al. Characterization of porcine immunoglobulin deposition in human livers recovered using xenogeneic cross-circulation. ASAIO. 2024.